Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Serial non-invasive assessment of antibody induced nephritis in mice using positron emission tomography.

Hao G, Du Y, Zhou XJ, Guo J, Sun X, Mohan C, Oz OK.

PLoS One. 2013;8(2):e57418. doi: 10.1371/journal.pone.0057418. Epub 2013 Feb 27.

2.

Serial non-invasive monitoring of renal disease following immune-mediated injury using near-infrared optical imaging.

Du Y, An S, Liu L, Li L, Zhou XJ, Mason RP, Mohan C.

PLoS One. 2012;7(9):e43941. doi: 10.1371/journal.pone.0043941. Epub 2012 Sep 26.

3.

Excreted urinary mediators in an animal model of experimental immune nephritis with potential pathogenic significance.

Wu T, Xie C, Bhaskarabhatla M, Yan M, Leone A, Chen SS, Zhou XJ, Putterman C, Mohan C.

Arthritis Rheum. 2007 Mar;56(3):949-59.

4.
5.

Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and "cystic" kidneys. a case series.

Piccoli GB, Arena V, Consiglio V, Deagostini MC, Pelosi E, Douroukas A, Penna D, Cortese G.

BMC Nephrol. 2011 Sep 29;12:48. doi: 10.1186/1471-2369-12-48.

6.

Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.

Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N.

BMC Cancer. 2010 Dec 3;10:667. doi: 10.1186/1471-2407-10-667.

7.

Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomography.

Brewer S, McPherson M, Fujiwara D, Turovskaya O, Ziring D, Chen L, Takedatsu H, Targan SR, Wei B, Braun J.

Gastroenterology. 2008 Sep;135(3):744-55. doi: 10.1053/j.gastro.2008.06.040. Epub 2008 Jul 17.

8.

Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease.

Bleeker-Rovers CP, de Sévaux RG, van Hamersvelt HW, Corstens FH, Oyen WJ.

Am J Kidney Dis. 2003 Jun;41(6):E18-21.

PMID:
12776306
9.

Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.

Jensen MM, Erichsen KD, Björkling F, Madsen J, Jensen PB, Højgaard L, Sehested M, Kjær A.

PLoS One. 2010 Sep 24;5(9):e12965. doi: 10.1371/journal.pone.0012965.

10.

2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses.

Kumar R, Chauhan A, Lakhani P, Xiu Y, Zhuang H, Alavi A.

Mol Imaging Biol. 2005 Nov-Dec;7(6):431-9.

PMID:
16307216
11.

[F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model.

Chaise C, Itti E, Petegnief Y, Wirquin E, Copie-Bergman C, Farcet JP, Delfau-Larue MH, Meignan M, Talbot JN, Molinier-Frenkel V.

Cancer Immunol Immunother. 2007 Aug;56(8):1163-71. Epub 2006 Dec 14.

12.

Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.

McLarty K, Moran MD, Scollard DA, Chan C, Sabha N, Mukherjee J, Guha A, McLaurin J, Nitz M, Houle S, Wilson AA, Reilly RM, Vasdev N.

Nucl Med Biol. 2011 Oct;38(7):953-9. doi: 10.1016/j.nucmedbio.2011.02.017. Epub 2011 May 6.

PMID:
21982567
13.

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M.

J Clin Oncol. 2009 Jun 1;27(16):2697-704. doi: 10.1200/JCO.2008.18.8383. Epub 2009 Apr 20.

14.

Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.

Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, Brillouet S, Canal P, Courbon F, Allal BC.

Clin Cancer Res. 2010 Sep 1;16(17):4434-45. doi: 10.1158/1078-0432.CCR-09-2795. Epub 2010 Jul 26.

15.

Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer.

Apolo AB, Riches J, Schöder H, Akin O, Trout A, Milowsky MI, Bajorin DF.

J Clin Oncol. 2010 Sep 1;28(25):3973-8. doi: 10.1200/JCO.2010.28.7052. Epub 2010 Aug 2.

16.

Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.

Everitt S, Hicks RJ, Ball D, Kron T, Schneider-Kolsky M, Walter T, Binns D, Mac Manus M.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1098-104. doi: 10.1016/j.ijrobp.2008.12.039. Epub 2009 Apr 20.

PMID:
19386444
17.

In vivo molecular imaging of experimental joint inflammation by combined (18)F-FDG positron emission tomography and computed tomography.

Irmler IM, Opfermann T, Gebhardt P, Gajda M, Bräuer R, Saluz HP, Kamradt T.

Arthritis Res Ther. 2010;12(6):R203. doi: 10.1186/ar3176. Epub 2010 Nov 3.

18.

Early detection of bone infection and differentiation from post-surgical inflammation using 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography (FDG-PET) in an animal model.

Jones-Jackson L, Walker R, Purnell G, McLaren SG, Skinner RA, Thomas JR, Suva LJ, Anaissie E, Miceli M, Nelson CL, Ferris EJ, Smeltzer MS.

J Orthop Res. 2005 Nov;23(6):1484-9.

19.
20.

The effect of PPAR-gamma agonist on (18)F-FDG uptake in tumor and macrophages and tumor cells.

Kim SL, Kim EM, Cheong SJ, Lee CM, Kim DW, Jeong HJ, Lim ST, Sohn MH, Yim CY.

Nucl Med Biol. 2009 May;36(4):427-33. doi: 10.1016/j.nucmedbio.2009.01.010. Epub 2009 Mar 26.

PMID:
19423011
Items per page

Supplemental Content

Write to the Help Desk